lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. MW : 145.5 KD.
Supplier Selleck Chemicals
Product # A2330
Sku # A2330-1mg*5
Pricing 1mg*5, $790.00
Feedback